Dog Alaskan Malamute Polyneuropathy (AMPN)

Alaskan Malamute Polyneuropathy (AMPN) is a genetic disorder that affects the nervous system of Alaskan Malamutes. A DNA test for AMPN can help dog owners identify whether their pets are carriers of this condition, which may lead to debilitating symptoms such as muscle weakness and impaired coordination. Early detection through DNA testing is crucial for managing the health of affected dogs, allowing for better care and informed breeding decisions. By knowing your dog's genetic status, you can take proactive steps to ensure a healthier life for your Alaskan Malamute. Don't wait—consider a DNA test today to safeguard your furry friend against AMPN. Protect your dog's well-being with this simple yet essential genetic screening.

Abbreviation : AMPN

Analysed mutation : NDRG1 c.293G>T

Inheritance : Autosomal Recessive

Acronym

AMPN

Observed frequency

Normal

Clinical severity

Moderate

Clinical classification

Neurological Diseases

Analysed mutation

NDRG1 c.293G>T
p.(G98V)

Mode of inheritance

Autosomal Recessive

Test summary:

Alaskan Malamute Polyneuropathy (AMPN) is a genetic condition affecting the nervous system of Alaskan Malamutes. DNA testing for AMPN helps identify carriers and affected dogs, allowing breeders to make informed decisions to reduce the prevalence of this disorder. Symptoms may include muscle weakness and coordination issues, impacting the dog's quality of life. Early detection through genetic testing can aid in managing the condition effectively. Responsible breeding practices can help ensure healthier future generations of this beloved breed.

Available from the pack : Basic

This DNA test is included starting from our pack Basic — and is also part of the packs Basic, Standard, Advanced, Complete.

View DNA Test Packs →

Choose the pack that best fits your breeding or health strategy of your animals.

Understanding Alaskan Malamute Polyneuropathy (AMPN)

Alaskan Malamute Polyneuropathy (AMPN) is a hereditary neurological disorder that primarily affects Alaskan Malamutes, leading to a range of debilitating symptoms. This condition is characterized by the degeneration of peripheral nerves, which can result in significant mobility issues and impairments in the dog's overall quality of life.

Symptoms of AMPN

Dogs affected by AMPN may exhibit a variety of symptoms, which can vary in severity. Common signs include muscle weakness, difficulty in walking or running, and a noticeable decrease in coordination. As the disease progresses, affected dogs may develop tremors, a wobbly gait, and muscle atrophy. These symptoms often manifest between the ages of 6 months and 2 years, although the onset can vary.

Genetic Basis of AMPN

The condition is caused by a genetic mutation that affects the structure and function of nerve fibers. This mutation can be identified through a DNA test, which helps in diagnosing the condition before clinical signs become apparent. Understanding the genetic basis of AMPN is crucial for breeders and pet owners, as it aids in making informed decisions regarding breeding practices and the management of affected dogs.

Importance of DNA Testing

DNA testing for AMPN plays a vital role in the early detection and management of the disease. By identifying carriers of the genetic mutation, breeders can take steps to avoid mating affected dogs, thereby reducing the incidence of the disorder in future generations. Moreover, knowing a dog’s genetic status can assist owners in making informed decisions about their pet’s care and potential lifestyle adjustments.

Managing AMPN

While there is currently no cure for AMPN, management strategies can significantly improve the quality of life for affected dogs. These may include physical therapy, pain management, and modifications to the dog's environment to accommodate mobility challenges. Regular veterinary check-ups are essential to monitor the condition and adjust treatment plans as needed.

Conclusion

Alaskan Malamute Polyneuropathy is a serious genetic condition that can severely impact the health and well-being of affected dogs. Through DNA testing, owners and breeders can take proactive steps in managing this disorder, ensuring that future generations of Alaskan Malamutes are healthier and less prone to AMPN. Understanding the implications of this condition is crucial for responsible breeding and compassionate care of affected dogs.

Breed recognized for the test : Alaskan Malamute Polyneuropathy (AMPN)

Alaskan Malamute

Interpretation of genotypes Genotype Status Learn more about the interpretation of genotypes FAQ: understanding the interpretation of result What does “Clear” mean? The animal does not carry the mutation. It will not develop the disease and will not pass it on. Is a “Carrier” serious? No. The animal is generally healthy but can transmit the mutation to its offspring. What if an animal is “Affected”? It carries two mutated copies. Clinical signs are expected depending on the disease. It should not be bred. Why are there differences between male / female? Some diseases are sex-linked, so their expression varies depending on the animal’s sex. The animal has two normal copies of the gene. No risk of developing or transmitting the disease. Heterozygous carrier: one mutated copy. The animal is usually not clinically affected but can pass the mutation to offspring. Male carrier or affected depending on the inheritance mode. Males have only one X or Y chromosome. Heterozygous female carrier: one mutated copy. She can pass the mutation on and may sometimes show mild clinical signs depending on the condition. Two mutated copies of the gene. The animal is at risk of developing the associated condition.

🧬 Interpretation of genotypes AMPN

Genotype

Status

🟡 N/N

Non-carrier - No Risk

🟡 N/AMPN

Carrier - No Risk

❌ AMPN/AMPN

Affected - At Risk

FAQ: understanding the interpretation

What does “Clear” mean?

The animal does not carry the mutation. It will not develop the disease and will not pass it on.

Is a “Carrier” serious?

No. The animal is generally healthy but can transmit the mutation to its offspring.

What if an animal is “Affected”?

It carries two mutated copies. Clinical signs are expected depending on the disease. It should not be bred.

Why are there differences between male / female?

Some diseases are sex-linked, so their expression varies depending on the animal’s sex.

Genotype Forecast for Offspring Mother Father Non-carrier Carrier Affected Favorable cross: majority Carrier risk is predominant. Majority affected Filter by mother's genotype Filter by father's genotype All Predict Offspring The animal has two normal copies of the gene. No risk of developing or transmitting the disease. Heterozygous carrier: one mutated copy. The animal is usually not clinically affected but can pass the mutation to offspring. Male carrier or affected depending on the inheritance mode. Males have only one X or Y chromosome. Heterozygous female carrier: one mutated copy. She can pass the mutation on and may sometimes show mild clinical signs depending on the condition. Two mutated copies of the gene. The animal is at risk of developing the associated condition.

Predict Offspring

Filter by mother's genotype Filter by father's genotype

N/N (Non-carrier)

N/AMPN (Carrier)

AMPN/AMPN (Affected)

DNA Test FAQ

What does this DNA test detect?

This DNA test detects the mutation associated with Alaskan Malamute Polyneuropathy (AMPN) in order to identify clear, carrier, or at-risk animals.

Why test a breeding animal?

DNA testing helps breeders plan safer matings and reduce the risk of transmitting the mutation to offspring.

What is the inheritance mode of this test?

The inheritance mode reported for this test is Autosomal Recessive.

Which mutation is analysed in this test?

This test analyses the mutation NDRG1 c.293G>T.

Is a carrier animal necessarily affected?

Not necessarily. Interpretation depends on the inheritance pattern and the resulting genotype.

References

Bruun Camilla S, Jäderlund Karin H, Berendt Mette, Jensen Kristine B, Spodsberg Eva H, Gredal Hanne, Shelton G Diane, Mickelson James R, Minor Katie M, Lohi Hannes, Bjerkås Inge, Stigen Oyvind, Espenes Arild, Rohdin Cecilia, Edlund Rebecca, Ohlsson Jennie, Cizinauskas Sigitas, Leifsson Páll S, Drögemüller Cord, Moe Lars, Cirera Susanna, Fredholm Merete. A Gly98Val mutation in the N-Myc downstream regulated gene 1 (NDRG1) in Alaskan Malamutes with polyneuropathy. PLoS One. 2013;8(2):e54547. doi: 10.1371/journal.pone.0054547. Epub 2013 Feb 5.

My DNA Portal